3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
8
Gastrointestinal
3
Head & Neck
2
Conditions
Squamous Cell Carcinoma of Head and Neck
2
Interventions
Cisplatin
30
pembrolizumab
24
Magnetic Resonance Spectroscopy
24
Specimen Handling
20
Cetuximab
18
Nivolumab
15
Carboplatin
14
Platinum
12
1,2-diaminocyclohexaneplatinum II citrate
12
Radiotherapy, Intensity-Modulated
11
Radiotherapy
10
Radiation
9
Paclitaxel
9
Docetaxel
8
Biopsy
8
Immunoglobulin G
7
Disulfides
7
Surveys and Questionnaires
6
Ipilimumab
6
atezolizumab
5
Fluorouracil
5
toripalimab
4
dostarlimab
4
cemiplimab
4
cabozantinib
4
Taxes
4
Gemcitabine
4
CTLA-4 Antigen
4
Bevacizumab
4
(225)Ac-DOTA-c(RGDyK)
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
amivantamab
×
Head & Neck
×
30 days
×
Clear all
NCT06385080
2026-06-05
OrigAMI-4
Janssen Research & Development, LLC
Phase 1/2
Recruiting
287 enrolled
NCT07276399
2026-06-05
OrigAMI-5
Janssen Research & Development, LLC
Phase 3
Recruiting
500 enrolled